SLC5A2 and hydrops fetalis: The CANVAS Program data provide clear evidence of the protective effects of canagliflozin on HF and, in conjunction with EMPA-REG OUTCOME, suggest an important role for SGLT2 inhibitors in the prevention of HF among patients with type 2 diabetes mellitus.